SG11201610862VA - Humanized anti-tau antibodies - Google Patents

Humanized anti-tau antibodies

Info

Publication number
SG11201610862VA
SG11201610862VA SG11201610862VA SG11201610862VA SG11201610862VA SG 11201610862V A SG11201610862V A SG 11201610862VA SG 11201610862V A SG11201610862V A SG 11201610862VA SG 11201610862V A SG11201610862V A SG 11201610862VA SG 11201610862V A SG11201610862V A SG 11201610862VA
Authority
SG
Singapore
Prior art keywords
humanized anti
tau antibodies
tau
antibodies
humanized
Prior art date
Application number
SG11201610862VA
Inventor
Tim West
Diljeet S Athwal
Timothy D Jones
Francis J Carr
Robert George Edward Holgate
Original Assignee
C2N Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C2N Diagnostics Llc filed Critical C2N Diagnostics Llc
Publication of SG11201610862VA publication Critical patent/SG11201610862VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
SG11201610862VA 2014-06-27 2015-06-26 Humanized anti-tau antibodies SG11201610862VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462018436P 2014-06-27 2014-06-27
US201462080903P 2014-11-17 2014-11-17
US201562170036P 2015-06-02 2015-06-02
PCT/US2015/038002 WO2015200806A2 (en) 2014-06-27 2015-06-26 Humanized anti-tau antibodies

Publications (1)

Publication Number Publication Date
SG11201610862VA true SG11201610862VA (en) 2017-01-27

Family

ID=54938957

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201610862VA SG11201610862VA (en) 2014-06-27 2015-06-26 Humanized anti-tau antibodies
SG10201914067XA SG10201914067XA (en) 2014-06-27 2015-06-26 Humanized anti-tau antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201914067XA SG10201914067XA (en) 2014-06-27 2015-06-26 Humanized anti-tau antibodies

Country Status (27)

Country Link
US (2) US9957317B2 (en)
EP (1) EP3182987B1 (en)
JP (3) JP6626892B2 (en)
KR (1) KR102431596B1 (en)
CN (1) CN106659759B (en)
AU (2) AU2015279643B2 (en)
BR (1) BR112016030686A2 (en)
CA (2) CA2953809C (en)
CL (1) CL2016003346A1 (en)
CR (1) CR20170026A (en)
DO (1) DOP2016000335A (en)
EC (1) ECSP17005649A (en)
ES (1) ES2959528T3 (en)
IL (3) IL249734B (en)
MA (1) MA40229A (en)
MX (2) MX2017000205A (en)
MY (1) MY184540A (en)
NZ (1) NZ727919A (en)
PE (1) PE20170665A1 (en)
PH (2) PH12016502608A1 (en)
RU (1) RU2743152C2 (en)
SG (2) SG11201610862VA (en)
TW (3) TW202136296A (en)
UA (1) UA122771C2 (en)
UY (1) UY36194A (en)
WO (1) WO2015200806A2 (en)
ZA (1) ZA201608875B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877397A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
CU24446B1 (en) 2013-03-13 2019-10-04 Prothena Biosciences Ltd A HUMANIZED MONOCLONAL ANTIBODY JOINING TAU
TW202136296A (en) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 Humanized anti-tau antibodies
MX2017015464A (en) 2015-06-05 2018-03-28 Genentech Inc Anti-tau antibodies and methods of use.
US20200030445A1 (en) * 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
EP4124362A1 (en) 2016-04-18 2023-02-01 Faron Pharmaceuticals OY Methods of monitoring a modulation of m2 macrophages into m1 macrophages
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
JP7170316B2 (en) * 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド Tau immunotherapy
CU24538B1 (en) 2016-05-02 2021-08-06 Prothena Biosciences Ltd MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 16G7 ANTIBODY
US10570196B2 (en) * 2016-07-20 2020-02-25 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
IL300982B1 (en) * 2016-09-10 2024-04-01 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity fortreatment of " disease and injury of the cns
KR20190054094A (en) 2016-09-27 2019-05-21 세로 테라퓨틱스, 인코포레이티드 Chimeric phagocytic receptor molecule
KR20230146126A (en) 2016-12-07 2023-10-18 제넨테크, 인크. Anti-tau antibodies and methods of use
JP2020511937A (en) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド Anti-TAU antibody and method of use
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (en) 2017-02-27 2018-09-13 帝人ファーマ株式会社 Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same
EP3601337A1 (en) 2017-03-28 2020-02-05 Genentech, Inc. Methods of treating neurodegenerative diseases
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
EP3688032A1 (en) 2017-09-26 2020-08-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
MX2020003581A (en) 2017-10-02 2020-07-22 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections.
MX2020003857A (en) 2017-10-16 2021-01-08 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof.
AU2019237252A1 (en) * 2018-03-23 2020-10-22 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
US11987631B2 (en) 2018-08-01 2024-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
WO2021010712A1 (en) * 2019-07-15 2021-01-21 주식회사 아델 Anti-tau antibody and use of same
AU2020325770B2 (en) 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
MX2022016322A (en) 2020-06-25 2023-01-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413.
TW202328177A (en) 2021-08-27 2023-07-16 美商建南德克公司 Methods of treating tau pathologies
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023178049A1 (en) 2022-03-14 2023-09-21 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
WO2023250326A1 (en) 2022-06-21 2023-12-28 Genentech, Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses
CN115724970B (en) * 2022-07-27 2023-10-20 生工生物工程（上海）股份有限公司 Binding protein capable of specifically binding E-CAD polypeptide and application thereof
CN116375857A (en) * 2023-03-30 2023-07-04 天津鸿宇泰生物科技有限公司 Single-chain antibody for detecting Tau protein, and preparation method and application thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK546988A (en) 1987-10-02 1989-04-03 Du Pont IMMUNE DETERMINATION AND THE REAGENT SITE USED HEREIN
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
WO1993008302A1 (en) 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
DE69233767D1 (en) 1991-12-06 2009-09-17 Max Planck Gesellschaft Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH06239899A (en) 1993-02-12 1994-08-30 Teijin Ltd Antibody for human tau protein and determination of human tau protein in body fluid utilizing the same
US6121003A (en) 1994-07-29 2000-09-19 Innogentics N.V. Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
WO1997034145A1 (en) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Antiphosphorylated tau protein antibody and method for detecting alzheimer's disease with the use of the same
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
JP4624559B2 (en) 1998-09-08 2011-02-02 イノジェネティックス・ナムローゼ・フェンノートシャップ Tau as a marker of initial CNS damage
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
JP4582874B2 (en) 2000-07-13 2010-11-17 富士通株式会社 Polarization mode dispersion compensation method and polarization mode dispersion compensation apparatus
AT500379B8 (en) * 2001-02-02 2009-08-15 Axon Neuroscience TAU PROTEINS
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
EP1464702A4 (en) 2001-12-28 2005-09-21 Chugai Pharmaceutical Co Ltd Method of stabilizing protein
PT1507556T (en) 2002-05-02 2016-09-28 Wyeth Holdings Llc Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AU2003246664B2 (en) 2002-07-12 2007-06-14 Axon Neuroscience Se Transgenic animal expressing Alzheimer's tau protein
ES2352668T3 (en) 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation SPECIFIC ANTIBODY FOR A TAU PROTEIN OF THE CENTRAL NERVOUS SYSTEM.
FI20030652A0 (en) 2003-04-30 2003-04-30 Susann Eriksson Improved immune determination
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
ATE440949T1 (en) * 2004-01-30 2009-09-15 Maxygen Holdings Ltd CONTROLLED READING OF STOPCODONS
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
WO2006088281A1 (en) 2005-02-19 2006-08-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
WO2007019273A2 (en) 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
ES2321996B1 (en) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas USE OF COMPOUNDS THAT JOIN THE DOMAIN OF UNION TO TAU MICROTUBLES IN THE DEVELOPMENT OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THE TREATMENT OF TAUOPATIAS.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
ES2673822T3 (en) * 2006-07-18 2018-06-25 Sanofi Antagonist antibody against EphA2 for cancer treatment
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
PT2276485E (en) 2008-04-24 2014-10-20 Bristol Myers Squibb Co Use of epothilone d in treating tau-associated diseases including alzheimer's disease
CN101307108B (en) 2008-06-25 2012-04-04 南京川博生物技术有限公司 Anti-phosphorylation Tau protein antibody use for detecting AD sign abnormal phosphation Tau protein level
KR101814408B1 (en) * 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
UA107571C2 (en) 2009-04-03 2015-01-26 PHARMACEUTICAL COMPOSITION
WO2010129674A2 (en) 2009-05-05 2010-11-11 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP5917394B2 (en) 2009-06-10 2016-05-11 ニューヨーク・ユニバーシティ Immunological targeting method of pathological tau protein
WO2010146792A1 (en) 2009-06-17 2010-12-23 株式会社フジクラ Multiclad optical fiber, optical fiber module, fiber laser, and fiber amplifier
KR20130127547A (en) 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 Antigenic tau peptides and uses thereof
WO2011026031A1 (en) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
WO2011045166A1 (en) 2009-09-24 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011109112A2 (en) 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
CN102939305B (en) * 2010-04-08 2016-08-17 Jn生物科学有限责任公司 Antibody to CD122
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
PL2625198T3 (en) 2010-10-07 2015-12-31 Ac Immune Sa Antibodies recognising phospho-tau
CA2813493C (en) * 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
EP2709728B1 (en) 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013012811A2 (en) 2011-07-19 2013-01-24 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
CN109265543B (en) 2011-09-19 2022-04-26 阿克松神经***科学公司 Protein-based therapy and diagnosis of TAU protein-mediated pathologies in alzheimer's disease
BR122021017560B1 (en) 2011-10-07 2023-03-07 Katholieke Universiteit Leuven ANTIBODY, POLYNUCLEOTIDE, PHARMACEUTICAL COMPOSITION, USES OF AN ANTIBODY, IN VITRO METHOD, POST-MORTEM DETECTION METHOD OF PHOSPHO-TAU MULTIMERS, IN VITRO METHOD OF DETECTION OF THE FORMATION OF AN IMMUNE COMPLEX, TEST KITS, ISOLATED CELL LINE AND METHOD OF IN VITRO DETECTION OF PHOSPHO-TAU MULTIMERS
CA2853100A1 (en) 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
SG11201401319XA (en) * 2011-10-27 2014-06-27 Nkt Therapeutics Inc Humanized antibodies to inkt
EA027975B1 (en) 2011-12-20 2017-09-29 Янссен Байотек, Инк. Anti-phf-tau antibodies and their uses
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
CN104520322B (en) 2012-04-05 2019-11-15 Ac免疫有限公司 Humanization TAU antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
TWI700296B (en) 2012-05-31 2020-08-01 公立大學法人大阪市立大學 Dementia treatment or prevention agent
CA2877397A1 (en) * 2012-07-03 2014-01-09 Washington University Antibodies to tau
MY176838A (en) * 2012-08-16 2020-08-24 Ipierian Inc Methods of treating a tauopathy
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
CA2885924C (en) 2012-08-21 2022-12-13 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
AU2013328881B2 (en) 2012-10-12 2018-03-15 Arizona Board Of Regents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9910048B2 (en) 2012-12-03 2018-03-06 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
LT2935326T (en) 2012-12-21 2020-12-10 Biogen Ma Inc. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CU24446B1 (en) 2013-03-13 2019-10-04 Prothena Biosciences Ltd A HUMANIZED MONOCLONAL ANTIBODY JOINING TAU
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
US9688747B2 (en) 2013-03-15 2017-06-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
KR102233349B1 (en) 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. Anti-tau antibodies and methods of use
TW202136296A (en) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 Humanized anti-tau antibodies

Also Published As

Publication number Publication date
RU2017102514A (en) 2018-07-31
MA40229A (en) 2021-06-02
US9957317B2 (en) 2018-05-01
EP3182987B1 (en) 2023-09-27
IL273656B (en) 2022-01-01
BR112016030686A2 (en) 2017-10-31
ZA201608875B (en) 2017-09-27
CN106659759A (en) 2017-05-10
AU2021204800A1 (en) 2021-08-05
DOP2016000335A (en) 2017-04-17
TWI664190B (en) 2019-07-01
CR20170026A (en) 2017-06-16
CA3094638A1 (en) 2015-12-30
CA2953809C (en) 2020-09-29
KR20170026390A (en) 2017-03-08
UY36194A (en) 2016-01-29
ES2959528T3 (en) 2024-02-26
IL288649A (en) 2022-02-01
EP3182987A4 (en) 2018-01-24
MX2021008888A (en) 2021-08-19
AU2015279643B2 (en) 2021-04-08
JP2022050392A (en) 2022-03-30
JP2017521097A (en) 2017-08-03
RU2017102514A3 (en) 2019-02-25
WO2015200806A2 (en) 2015-12-30
UA122771C2 (en) 2021-01-06
WO2015200806A3 (en) 2016-02-25
CL2016003346A1 (en) 2017-07-21
SG10201914067XA (en) 2020-03-30
IL249734B (en) 2020-03-31
IL273656A (en) 2020-05-31
MY184540A (en) 2021-04-01
PH12016502608A1 (en) 2017-04-24
JP2020054356A (en) 2020-04-09
TW202136296A (en) 2021-10-01
EP3182987C0 (en) 2023-09-27
KR102431596B1 (en) 2022-08-12
CN106659759B (en) 2022-04-15
CA2953809A1 (en) 2015-12-30
NZ727919A (en) 2021-07-30
RU2743152C2 (en) 2021-02-15
IL249734A0 (en) 2017-02-28
MX2017000205A (en) 2017-08-22
PH12021550023A1 (en) 2021-12-13
PE20170665A1 (en) 2017-06-10
ECSP17005649A (en) 2018-04-30
JP6626892B2 (en) 2019-12-25
TWI734975B (en) 2021-08-01
EP3182987A2 (en) 2017-06-28
AU2015279643A1 (en) 2017-01-19
US20170058024A1 (en) 2017-03-02
TW201607956A (en) 2016-03-01
US20180371066A1 (en) 2018-12-27
TW201946931A (en) 2019-12-16

Similar Documents

Publication Publication Date Title
IL288649A (en) Humanized anti-tau antibodies
ZA201803874B (en) Humanized anti-cd73 antibodies
IL250583A0 (en) Anti-tigit antibodies
HK1258375A1 (en) Humanized anti-cll-1 antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
IL256579A (en) Humanized antibodies
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
PT3101131T (en) Anti-transthyretin humanized antibody
IL262776A (en) Humanized anti-il-1r3 antibodies
IL250374B (en) Anti-ceramide antibodies
EP3131581A4 (en) Humanized anti-tf-antigen antibodies
IL246603A0 (en) Novel anti-netrin-1 antibody
PL3371216T3 (en) Humanized anti-bag3 antibodies
IL247988A0 (en) Antibodies against hpa-1a
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies